KENILWORTH, N.J., June 6 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced plans to adopt a new global model for its clinical trial operations, designed to maximize its product portfolio through centralized global processes and functional units that are efficient, compliant and customer-focused. This model is expected to further enhance how the company plans and manages the progression of therapeutic compounds through clinical trials toward commercialization.
"When fully implemented, the new model we are adopting is designed to result in a global, standardized approach to how we conduct clinical trials," said Brent Saunders, senior vice president, Global Compliance and Business Practices, and project executive chair. "This new model, which replaces a previously decentralized approach, should help ensure better planning and prioritization, greater consistency in trial execution and improved cost efficiencies."
Said Fred Hassan, chairman and CEO: "This new global model for clinical trials is another step in our Action Agenda to transform Schering-Plough into a high-performance competitor for the long term. Globalizing these activities will further enhance the quality and consistency of our clinical trials and our capabilities to bring new treatments to physicians and patients."
Under the Global Clinical Harmonization (GCH) program, all clinical trials will be held to a consistent set of standards regardless of trial type, phase or geography. Global Clinical Operations (GCO) will establish this global set of standards, policies and practices, and build a management system that will oversee clinical trials worldwide.
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including statements relating to improved productivity and efficiencies under the Global Clinical Harmonization program. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, changes to and ability to successfully implement the company's business strategy, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A. Risk Factors in the Company's 2005 10-K.
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 32,000 people around the world.
The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com .
Schering-Plough CorporationCONTACT: Media: Steve Galpin, Jr., +1-908-298-7415, or Investor: AlexKelly, +1-908-298-7436, both of Schering-Plough Corporation
Web site: http://www.schering-plough.com/
Company News On-Call: http://www.prnewswire.com/comp/777050.html /
